Treatment with the CTLA4-Ig (Abatacept) bDMARD has been shown to induce a shift in macrophage polarisation, based on their plasticity, from a pro-inflammatory M1 phenotype to an anti-inflammatory M2 phenotype in both MDMs from healthy and active RA patients [161]. Here, CTLA4 is linked to rheumatoid arthritis.